Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
American Journal of Human Genetics|March 11, 2025
The expanding global genomics landscape: Converging priorities from national genomics programsCaitlin Howley, Matilda A Haas, Wadha A Al Muftah, et al.
Ugeskrift for Laeger|February 24, 2006
[Epidemic increase in methicillin-resistant Staphylococcus aureus in Copenhagen]Henrik Westh, Kit Boye, Mette Damkjaer Bartels, et al.
Seminars in Thrombosis and Hemostasis|January 16, 2015
Profound endothelial damage predicts impending organ failure and death in sepsisMaria E Johansen, Pär I Johansson, Sisse R Ostrowski, et al.
Annals of Intensive Care|November 23, 2016
Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trialJens-Ulrik S Jensen, Theis S Itenov, Katrin M Thormar, et al.
Journal of Internal Medicine|July 16, 2023
Implementation of precision medicine in healthcare-A European perspectiveAlbrecht Stenzinger, Ejner K Moltzen, Eva Winkler, et al.
Critical Care Medicine|May 17, 2011
Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trialJens U Jensen, Lars Hein, Bettina Lundgren, et al.
BMJ Open|March 14, 2012
Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trialJens-Ulrik Stæhr Jensen, Lars Hein, Bettina Lundgren, et al.
Critical Care Medicine|December 11, 2014
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroximeJens-Ulrik S Jensen, Lars Hein, Bettina Lundgren, et al.
BMC Infectious Diseases|July 16, 2008
The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patientsJens-Ulrik Jensen, Bettina Lundgren, Lars Hein, et al.
Pageof 3